These data allow us to speculate that midostaurin can influence MRD and lead to improved quality of response and represent the basis for a planned study evaluating MRD in AML patients with FLT3 expression treated with midostaurin + chemotherapy. Here, FLT3 is linked to acute myeloid leukemia.